Fortrea Holdings Inc. (FTRE)
(Delayed Data from NSDQ)
$25.39 USD
+1.17 (4.83%)
Updated May 31, 2024 04:00 PM ET
After-Market: $25.42 +0.03 (0.12%) 7:58 PM ET
5-Strong Sell of 5 5
C Value F Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
FTRE 25.39 +1.17(4.83%)
Will FTRE be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for FTRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FTRE
Company News for Mar 12, 2024
Cognizant (CTSH), Microsoft Team Up to Streamline Healthcare
FTRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cognizant (CTSH) Expands Gen-AI Footprint With Flowsource
Cognizant (CTSH) Boosts Innovation With Microsoft AI Assistant
Cognizant (CTSH) Expands Healthcare Footprint With Fortrea Deal
Other News for FTRE
Fortrea Introduces Comprehensive Solution to Improve Diversity and Inclusion in Clinical Research
Fortrea Holdings introduces solution to improve diversity in clinical trials
Fortrea Holdings Inc (FTRE) CEO Acquires Additional Shares
American downgraded, United upgraded: Wall Street's top analyst calls
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Fortrea Holdings Inc. (FTRE) and Cellectis SA (CLLS)